AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22749633 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plans with justifiable deviations that might result in adverse effects
Number of subjects: 100
Study 22749633 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plans with unjustified deviations
Number of subjects: 100
Study 22749633 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plans with no discernible justification
Number of subjects: 100
Study 21413940 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae derivative AVAC(TM)
Number of subjects: 60
Study 21413940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19188680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bevacizumab (7.5 mg/kg) plus cisplatin/gemcitabine
Number of subjects: 1043
Study 19188680 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bevacizumab (15 mg/kg) plus cisplatin/gemcitabine
Number of subjects: 1043
Study 19188680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1043
Study 17434891 — intervention group
Group type: EXPERIMENTAL
Intervention: Type-D personality
Number of subjects: 154
Study 17434891 — intervention group
Group type: COMPARATOR
Intervention: ICD indication (primary vs. secondary)
Number of subjects: 154
Study 17434891 — intervention group
Group type: EXPERIMENTAL
Intervention: Time (baseline vs. 3 months)
Number of subjects: 154
Study 17434891 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analysis
Number of subjects: 154
Study 15715249 — intervention group
Group type: EXPERIMENTAL
Intervention: rK39 dipstick
Number of subjects: 80
Study 15715249 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (microscopic examinations of bone marrow and lymph node aspirates and immunofluorescent antibody tests)
Number of subjects: 80
Study 12575547 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuangcao Tuihuang Granule‐1 (SCTH‐1)
Number of subjects: 34
Study 12575547 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 8841868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 7.5 micrograms/kg and midazolam 0.075 mg/kg administered over 10 minutes
Number of subjects: 40
Study 8841868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 12.5 micrograms/kg and midazolam 0.125 mg/kg administered over 10 minutes
Number of subjects: 40
Study 8841868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 20.0 micrograms/kg and midazolam 0.200 mg/kg administered over 10 minutes
Number of subjects: 40
Study 8841868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 7.5 micrograms/kg and midazolam 0.075 mg/kg administered within 1 minute
Number of subjects: 40
Study 8841868 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C, D)
Number of subjects: 40
Study 1703327 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP‐Bleo regimen (6 courses at 3-week intervals)
Number of subjects: 115
Study 1703327 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate chemotherapy (2 CHOP‐Bleo courses, 2 CMED courses, 2 CHOP‐Bleo courses)
Number of subjects: 115
Study 7351906 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume fluid intake (mean excess, 47 ml per kilogram per day)
Number of subjects: 170
Study 7351906 — intervention group
Group type: COMPARATOR
Intervention: Low-volume fluid intake (only enough water to meet average estimated requirements)
Number of subjects: 170
Study 30474990 — intervention group
Group type: EXPERIMENTAL
Intervention: TakeCARE video bystander program
Number of subjects: 165
Study 30474990 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 165
Study 28228421 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3
Number of subjects: 118
Study 28228421 — intervention group
Group type: COMPARATOR
Intervention: Narrow-band UVB exposure
Number of subjects: 118
Study 25921377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 25921377 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg)
Number of subjects: 292
Study 25350959 — intervention group
Group type: EXPERIMENTAL
Intervention: lersivirine 750 mg qd
Number of subjects: 97
Study 25350959 — intervention group
Group type: EXPERIMENTAL
Intervention: lersivirine 1,000 mg qd
Number of subjects: 97
Study 25350959 — intervention group
Group type: COMPARATOR
Intervention: etravirine 200 mg bid
Number of subjects: 97
Study 22158138 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 set of 10 resistance exercises (RE1)
Number of subjects: 10
Study 22158138 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets of 10 resistance exercises (RE3)
Number of subjects: 10
Study 22158138 — intervention group
Group type: COMPARATOR
Intervention: No exercise (C)
Number of subjects: 10
Study 20441724 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (flexible-dose, mean dose 10.8 ± 5.7 mg/d)
Number of subjects: 25
Study 20441724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17922461 — intervention group
Group type: COMPARATOR
Intervention: Conventional adjuvant chemotherapy
Number of subjects: 151
Study 17922461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensified adjuvant chemotherapy
Number of subjects: 151
Study 16135353 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon bupivacaine 0.5%
Number of subjects: 40
Study 16135353 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 40
Study 12161491 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analog therapy
Number of subjects: 0
Study 12161491 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 10434215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow sevoflurane
Number of subjects: 254
Study 10434215 — intervention group
Group type: COMPARATOR
Intervention: Low-flow isoflurane
Number of subjects: 254
Study 8866626 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg weekly
Number of subjects: 12
Study 8866626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1636133 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative antibiotic use
Number of subjects: 90
Study 1636133 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 90
Study 6735625 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-metronidazole
Number of subjects: 188
Study 6735625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 188
Study 30537180 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 236
Study 30537180 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (IAsp)
Number of subjects: 236
Study 30537180 — intervention group
Group type: COMPARATOR
Intervention: Faster aspart and IAsp
Number of subjects: 236
Study 30103187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - up to 20 sessions
Number of subjects: 43
Study 30103187 — intervention group
Group type: COMPARATOR
Intervention: Attentional Bias Modification (ABM) - 8 sessions
Number of subjects: 43
Study 30103187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 43
Study 30103187 — intervention group
Group type: COMPARATOR
Intervention: Attentional Bias Modification (ABM)
Number of subjects: 43
Study 26718306 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-Provera (medroxyprogesterone acetate), one injection every 3 months for 6 months (2 doses)
Number of subjects: 146
Study 26718306 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclic Norethisterone acetate (NETA), 15 mg daily for 14 days per cycle for 6 months
Number of subjects: 146
Study 23554029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinetrol-XPur
Number of subjects: 95
Study 22584730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling-constraint group (n = 24)
Number of subjects: 47
Study 22584730 — intervention group
Group type: COMPARATOR
Intervention: Voluntary-constraint group (n = 23)
Number of subjects: 47
Study 22584730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after 12 months follow-up
Number of subjects: 47
Study 20727460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus cisplatin and gemcitabine
Number of subjects: 0
Study 20727460 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed plus cisplatin
Number of subjects: 0
Study 17967583 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT) in addition to conventional treatment
Number of subjects: 200
Study 17967583 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 200
Study 15774775 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-infusion fluorouracil (CIFU) 250 mg/m²/d for 56 days every 9 weeks for three cycles plus levamisole 50 mg tid for 3 days every other week
Number of subjects: 1135
Study 15774775 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (FU) 425 mg/m² and leucovorin (LV) 20 mg/m² daily for 5 days every 28 to 35 days for six cycles plus levamisole 50 mg tid for 3 days every other week
Number of subjects: 1135
Study 12491845 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited, group-based problem-solving training intervention
Number of subjects: 46
Study 12491845 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 46
Study 9810302 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic cream combined with lidocaine infiltration
Number of subjects: 100
Study 9810302 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine infiltration
Number of subjects: 100
Study 7622850 — intervention group
Group type: EXPERIMENTAL
Intervention: Takeda UA‐751
Number of subjects: 28
Study 7622850 — intervention group
Group type: EXPERIMENTAL
Intervention: Copal UA‐251
Number of subjects: 28
Study 7622850 — intervention group
Group type: EXPERIMENTAL
Intervention: Accutracker 1
Number of subjects: 28
Study 7622850 — intervention group
Group type: EXPERIMENTAL
Intervention: SpaceLabs 90207
Number of subjects: 28
Study 7622850 — intervention group
Group type: COMPARATOR
Intervention: Hawksley random‐zero sphygmomanometer
Number of subjects: 28
Study 2142428 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (600 mg per day for three months)
Number of subjects: 7
Study 2142428 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 7
Study 627161 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 0
Study 627161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincterotomy
Number of subjects: 0
Study 627161 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31099657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus cytoreductive nephrectomy (CRN)
Number of subjects: 0
Study 31099657 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib alone
Number of subjects: 0
Study 31099657 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred CRN after three cycles of sunitinib
Number of subjects: 0
Study 31099657 — intervention group
Group type: COMPARATOR
Intervention: Immediate CRN followed by sunitinib
Number of subjects: 0
Study 26538241 — intervention group
Group type: EXPERIMENTAL
Intervention: Group teletherapy (12 sessions)
Number of subjects: 105
Study 25770484 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical prostatectomy (RALP)
Number of subjects: 510
Study 25770484 — intervention group
Group type: COMPARATOR
Intervention: Open retropubic radical prostatectomy (RRP)
Number of subjects: 510
Study 22589376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 22589376 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX354-C 100 mg twice daily
Number of subjects: 160
Study 22589376 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX354-C 200 mg once daily
Number of subjects: 160
Study 21691341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness group (MG) training
Number of subjects: 75
Study 21691341 — intervention group
Group type: COMPARATOR
Intervention: Support group (SG)
Number of subjects: 75
Study 20017346 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapryl
Number of subjects: 86
Study 20017346 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapryl with carvedilol
Number of subjects: 86
Study 20017346 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol (monotherapy)
Number of subjects: 86
Study 16415642 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention
Number of subjects: 0
Study 16415642 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolytic therapy
Number of subjects: 0
Study 15253850 — intervention group
Group type: EXPERIMENTAL
Intervention: EM practitioners
Number of subjects: 17
Study 15253850 — intervention group
Group type: COMPARATOR
Intervention: Non-practitioners
Number of subjects: 17
Study 15253850 — intervention group
Group type: EXPERIMENTAL
Intervention: EM practitioners and Non-practitioners
Number of subjects: 17
Study 11391320 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital abnormalities present in children with CP (n=192)
Number of subjects: 192
Study 11391320 — intervention group
Group type: COMPARATOR
Intervention: Congenital abnormalities present in control children (n=551)
Number of subjects: 192
Study 11391320 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural abnormalities of the central nervous system in children with CP
Number of subjects: 192
Study 11391320 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-central nervous system abnormalities in children with CP
Number of subjects: 192
Study 9578521 — intervention group
Group type: EXPERIMENTAL
Intervention: VGB 100-150 mg/kg/day
Number of subjects: 42
Study 9578521 — intervention group
Group type: COMPARATOR
Intervention: Depot ACTH 10 IU/day
Number of subjects: 42
Study 7526056 — intervention group
Group type: EXPERIMENTAL
Intervention: moexipril 3.75 mg
Number of subjects: 200
Study 7526056 — intervention group
Group type: EXPERIMENTAL
Intervention: moexipril 7.5 mg
Number of subjects: 200
Study 7526056 — intervention group
Group type: EXPERIMENTAL
Intervention: moexipril 15 mg
Number of subjects: 200
Study 7526056 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 200
Study 3317356 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived hepatitis B vaccine (Engerix-B)
Number of subjects: 79
Study 3317356 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 79
Study 29321134 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic care model‐based intervention
Number of subjects: 404
Study 29321134 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 404
Study 26447462 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine or Olanzapine
Number of subjects: 218
Study 26447462 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine or Risperidone
Number of subjects: 218
Study 26447462 — intervention group
Group type: COMPARATOR
Intervention: HCRTR1 SNPs
Number of subjects: 218
Study 24065289 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular vein volume flow in patients
Number of subjects: 0
Study 24065289 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral vein volume flow in patients
Number of subjects: 0
Study 24065289 — intervention group
Group type: COMPARATOR
Intervention: Internal jugular vein volume flow in controls
Number of subjects: 0
Study 24065289 — intervention group
Group type: COMPARATOR
Intervention: Vertebral vein volume flow in controls
Number of subjects: 0
Study 22731679 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerized type I collagen (PC), weekly subcutaneous intralesional injections ranging from 0.2 mL to 1.0 mL (1.66 mg to 8.3 mg collagen) for 3 months.
Number of subjects: 31
Study 22731679 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MP), monthly subcutaneous intralesional injections of 0.1 mL (20 mg/mL each month) for 3 months.
Number of subjects: 31
Study 19795993 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser phototherapy (LPT) for 4 weeks
Number of subjects: 40
Study 19795993 — intervention group
Group type: COMPARATOR
Intervention: Inactive/placebo laser treatment
Number of subjects: 40
Study 18378030 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 30
Study 18378030 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 30
Study 18378030 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 30
Study 16245491 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback via a mirror during movement exercises
Number of subjects: 0
Study 11954842 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction, primary bone grafting, and external fixation for 3 weeks, followed by a plaster cast for an additional 3 weeks
Number of subjects: 45
Study 11954842 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and external fixation for 6 weeks
Number of subjects: 45
Study 10525492 — intervention group
Group type: EXPERIMENTAL
Intervention: G1837A allele of the ANP gene
Number of subjects: 0
Study 10525492 — intervention group
Group type: EXPERIMENTAL
Intervention: G664A mutation in exon 1 of the ANP gene
Number of subjects: 0
Study 7574508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg orally every 12 h for 2 days (group 1, 4 h sampling)
Number of subjects: 12
Study 7574508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg orally every 12 h for 2 days (group 2, 12 h sampling)
Number of subjects: 12
Study 7574508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg orally every 12 h for 2 days
Number of subjects: 12
Study 2197377 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained residents
Number of subjects: 48
Study 2197377 — intervention group
Group type: COMPARATOR
Intervention: Untrained residents
Number of subjects: 48
Study 1013693 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide and propranolol
Number of subjects: 1500
Study 1013693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 31567604 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training session
Number of subjects: 47
Study 31567604 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study 31504070 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training group
Number of subjects: 57
Study 31504070 — intervention group
Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 57
Study 28582885 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii training
Number of subjects: 6
Study 28582885 — intervention group
Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 6
Study 24668254 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session coping improvement group intervention
Number of subjects: 295
Study 24668254 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session interpersonal support group intervention
Number of subjects: 295
Study 24668254 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy upon request
Number of subjects: 295
Study 24668254 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 295
Study 23472957 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological Therapy (PT)
Number of subjects: 14
Study 23472957 — intervention group
Group type: COMPARATOR
Intervention: Articulation Therapy (AT)
Number of subjects: 14
Study 21592370 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (33 mg/m2)
Number of subjects: 89
Study 21592370 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly docetaxel (100 mg/m2)
Number of subjects: 89
Study 19808224 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% icodextrin (ICO)
Number of subjects: 201
Study 19808224 — intervention group
Group type: COMPARATOR
Intervention: 2.5% glucose (GLU)
Number of subjects: 201
Study 16721678 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME)
Number of subjects: 161
Study 16721678 — intervention group
Group type: COMPARATOR
Intervention: Control (surgical resection before TME)
Number of subjects: 161
Study 16721678 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) with preoperative therapy
Number of subjects: 161
Study 16721678 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) without preoperative therapy
Number of subjects: 161
Study 14967392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 14967392 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 0
Study 11338763 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Help Interventions (SHIP) for six weeks
Number of subjects: 169
Study 11338763 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Help Interventions (SHIP)
Number of subjects: 169
Study 11338763 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 169
Study 9391811 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural perineural injections
Number of subjects: 182
Study 9391811 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural perineural injections with triamcinolone (10 mg)
Number of subjects: 182
Study 9391811 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 182
Study 9391811 — intervention group
Group type: COMPARATOR
Intervention: Conventional posterior epidural injections
Number of subjects: 182
Study 9391811 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral local anaesthetic
Number of subjects: 182
Study 8198903 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SC (s.c. PCA)
Number of subjects: 60
Study 8198903 — intervention group
Group type: COMPARATOR
Intervention: Group IV (i.v. PCA)
Number of subjects: 60
Study 8198903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 2467095 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g daily of safflower oil (linoleic acid)
Number of subjects: 25
Study 2467095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25